ATE137968T1 - Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen - Google Patents

Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen

Info

Publication number
ATE137968T1
ATE137968T1 AT92115046T AT92115046T ATE137968T1 AT E137968 T1 ATE137968 T1 AT E137968T1 AT 92115046 T AT92115046 T AT 92115046T AT 92115046 T AT92115046 T AT 92115046T AT E137968 T1 ATE137968 T1 AT E137968T1
Authority
AT
Austria
Prior art keywords
oxothiazolidine
carboxylate
treatment
production
medicinal product
Prior art date
Application number
AT92115046T
Other languages
English (en)
Inventor
Dennis I Goldberg
David A Mark
W Bruce Rowe
Kathleen A Thompson
Original Assignee
Transcend Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transcend Therapeutics Inc filed Critical Transcend Therapeutics Inc
Application granted granted Critical
Publication of ATE137968T1 publication Critical patent/ATE137968T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT92115046T 1991-09-30 1992-09-03 Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen ATE137968T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76919491A 1991-09-30 1991-09-30

Publications (1)

Publication Number Publication Date
ATE137968T1 true ATE137968T1 (de) 1996-06-15

Family

ID=25084740

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92115046T ATE137968T1 (de) 1991-09-30 1992-09-03 Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen

Country Status (6)

Country Link
EP (1) EP0535390B1 (de)
JP (1) JPH05194269A (de)
AT (1) ATE137968T1 (de)
AU (1) AU655835B2 (de)
CA (1) CA2077966A1 (de)
DE (1) DE69210737T2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6060694A (en) * 1993-05-10 1994-11-17 Transcend Therapeutics, Inc Method for treating acquired immune deficiency syndrome
US6013632A (en) * 1997-01-13 2000-01-11 Emory University Compounds and their combinations for the treatment of influenza infection
US20100216116A1 (en) * 2007-06-08 2010-08-26 Ghent University Viral latency model

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335210A (en) * 1981-02-11 1982-06-15 Cornell Research Foundation Method of producing L-cysteine
US5214062A (en) * 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
AU661379B2 (en) * 1992-04-23 1995-07-20 Transcend Therapeutics, Inc Method of reducing or preventing toxicity associated with antiretroviral therapy

Also Published As

Publication number Publication date
AU2211592A (en) 1993-04-29
EP0535390B1 (de) 1996-05-15
DE69210737D1 (de) 1996-06-20
EP0535390A1 (de) 1993-04-07
JPH05194269A (ja) 1993-08-03
DE69210737T2 (de) 1996-10-02
CA2077966A1 (en) 1993-03-31
AU655835B2 (en) 1995-01-12

Similar Documents

Publication Publication Date Title
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE73663T1 (de) Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
DE69230046T2 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE69811371D1 (de) Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung
DE69528751D1 (de) Verwendung von Interferon-alpha 8 subtype zur Herstellung von Medikamenten zur Behandlung von Viralinfektionen der Leber
DE69535758D1 (de) Lipid-analoge zur behandlung von viralen infektionen
DE69826023D1 (de) Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome
ATE120954T1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines arzneimittels zur behandlung von aids.
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
ATE170075T1 (de) Antivirales arzneimittel enthaltend prostratin
DE3850154D1 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
DK0406745T3 (da) Antibiotiske GE 2270 faktorer A1, A2, A3 og H
ATE135223T1 (de) Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose
DK0451486T3 (da) Antibiotikum GE 2270 faktorer B1, B2, C1, C2, D1, D2, E og T
ATE137968T1 (de) Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen
ES2089286T3 (es) Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos.
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
KR890003373A (ko) 수면장애 및 우울증 치료에 화합물의 이용
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
EP0342565A3 (de) Verwendung des Thiazol-Derivates Tiprotimod zur Herstellung eines Mittels zur Therapie von Virusinfektionen
DE3783122D1 (de) Verwendung von rekombiniertem menschlichem alpha-interferon zur herstellung eines arzneimittels zur behandlung des aids-virus.
ATE174507T1 (de) Verwendung eines benzimidazolwurmmittels zur behandlung von mikrosporeninfektionen
DE69932741D1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
DE59107405D1 (de) Ein Imidazobenzodiazepin zur Behandlung von Schlafstörungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee